Aflibercept (Eylea) will soon be available in a 2-mg sterile prefilled syringe, according to a press release by Regeneron Pharmaceuticals. Prior to the FDA’s approval—which comes almost 3 years after the agency first cleared prefilled ranibizumab syringes—aflibercept had only been available in single-dose vials.

"This approval may help doctors more conveniently and efficiently deliver Eylea to appropriate patients," said George D. Yancopoulos, MD, PhD, Regeneron’s president and chief scientific officer.

Aflibercept is indicated to treat 4 retinal diseases—wet AMD, macular edema secondary to retinal vein occlusion, diabetic macular edema, and diabetic retinopathy. Regeneron expects the prefilled syringes to be available later this year.